WallStSmart

Abbott Laboratories (ABT)vsElectromed Inc (ELMD)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

Abbott Laboratories generates 62803% more annual revenue ($45.13B vs $71.75M). ELMD leads profitability with a 14.1% profit margin vs 13.9%. ELMD appears more attractively valued with a PEG of 0.35. ELMD earns a higher WallStSmart Score of 66/100 (B-).

ABT

Buy

56

out of 100

Grade: C

Growth: 4.0Profit: 6.0Value: 4.7Quality: 6.0
Piotroski: 4/9Altman Z: 2.71

ELMD

Strong Buy

66

out of 100

Grade: B-

Growth: 8.7Profit: 7.5Value: 5.3Quality: 7.8
Piotroski: 5/9Altman Z: 5.57
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

ABTSignificantly Overvalued (-28.5%)

Margin of Safety

-28.5%

Fair Value

$70.89

Current Price

$91.07

$20.18 premium

UndervaluedFair: $70.89Overvalued
ELMDSignificantly Overvalued (-63.4%)

Margin of Safety

-63.4%

Fair Value

$15.46

Current Price

$37.69

$22.23 premium

UndervaluedFair: $15.46Overvalued

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

ABT1 strengths · Avg: 9.0/10
Market CapQuality
$151.49B9/10

Large-cap with strong market position

ELMD6 strengths · Avg: 9.2/10
PEG RatioValuation
0.3510/10

Growing faster than its price suggests

EPS GrowthGrowth
66.7%10/10

Earnings expanding 66.7% YoY

Altman Z-ScoreHealth
5.5710/10

Safe zone — low bankruptcy risk

Return on EquityProfitability
20.6%9/10

Every $100 of equity generates 21 in profit

Operating MarginProfitability
20.3%8/10

Strong operational efficiency at 20.3%

Revenue GrowthGrowth
18.4%8/10

18.4% revenue growth

Areas to Watch

ABT1 concerns · Avg: 2.0/10
EPS GrowthGrowth
-19.7%2/10

Earnings declined 19.7%

ELMD2 concerns · Avg: 3.5/10
P/E RatioValuation
32.2x4/10

Premium valuation, high expectations priced in

Market CapQuality
$312.08M3/10

Smaller company, higher risk/reward

Comparative Analysis Report

WallStSmart Research

Bull Case : ABT

The strongest argument for ABT centers on Market Cap. PEG of 1.30 suggests the stock is reasonably priced for its growth.

Bull Case : ELMD

The strongest argument for ELMD centers on PEG Ratio, EPS Growth, Altman Z-Score. Revenue growth of 18.4% demonstrates continued momentum. PEG of 0.35 suggests the stock is reasonably priced for its growth.

Bear Case : ABT

The primary concerns for ABT are EPS Growth.

Bear Case : ELMD

The primary concerns for ELMD are P/E Ratio, Market Cap.

Key Dynamics to Monitor

ABT profiles as a value stock while ELMD is a growth play — different risk/reward profiles.

ABT carries more volatility with a beta of 0.65 — expect wider price swings.

ELMD is growing revenue faster at 18.4% — sustainability is the question.

ABT generates stronger free cash flow (916M), providing more financial flexibility.

Bottom Line

ELMD scores higher overall (66/100 vs 56/100) and 18.4% revenue growth. Both earn "Strong Buy" and "Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Abbott Laboratories

HEALTHCARE · MEDICAL DEVICES · USA

Abbott Laboratories is an American multinational medical devices and health care company with headquarters in Abbott Park, Illinois, United States. The company was founded by Chicago physician Wallace Calvin Abbott in 1888 to formulate known drugs; today, it sells medical devices, diagnostics, branded generic medicines and nutritional products. It split off its research-based pharmaceuticals business into AbbVie in 2013.

Visit Website →

Electromed Inc

HEALTHCARE · MEDICAL DEVICES · USA

Electromed, Inc. develops, manufactures, markets, and sells airway clearance therapy and related products that apply high-frequency chest wall oscillation (HFCWO) therapy in lung care for patients of all ages in the United States. and internationally. The company is headquartered in New Prague, Minnesota.

Want to dig deeper into these stocks?